Director Holdings
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your OBI notes
Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, confirms that following admission of the second tranche of new common shares at 8.00 a.m. on 22 November 2024 in relation to the Fundraising, the directors' interests in the Company are as follows:
| Director | Total number of common shares | % of issued share capital |
|---|---|---|
| Carolyn Cross 1 | 155,864,029 | 38.58% |
| Nicolas Loebel | 3,513,991 | 0.87% |
| Junaid Bajwa | 1,193,697 | 0.30% |
| Jean Duval | 1,163,529 | 0.29% |
| Michael Farrar | 484,806 | 0.12% |
| Jean Charest | 353,356 | 0.09% |
| Margaret Shaw | 213,853 | 0.05% |
1 Existing beneficial holding includes 118,091,377 shares held by Carolyn Cross, including via holdings in 100% owned companies, and 37,772,652 shares held by Robert Cross, husband of Carolyn Cross.
Ondine Biomedical Inc.
| Angelika Vance, Corporate Communications | +001 604 838 2702 |
| Singer Capital Markets (Nominated Adviser & Joint Broker) | |
| Phil Davies, Sam Butcher | +44 (0)20 7496 3000 |
| RBC Capital Markets (Joint Broker) | |
| Rupert Walford, Kathryn Deegan | +44 (0)20 7653 4000 |
| Vane Percy & Roberts (Media Contact) | |
| Simon Vane Percy, Amanda Bernard | +44 (0)77 1000 5910 |
About Ondine Biomedical Inc.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.